Aadi bioscience announces u.s. commercial launch and availability of fyarro™ for the treatment of adult patients with locally advanced unresectable or metastatic malignant pecoma

– fyarro™ added to nccn® guidelines as the only preferred mtor inhibitor to treat malignant pecoma – – precision-1 tumor agnostic study for tsc1 or tsc2 alterations is open for enrollment –

AADI Ratings Summary

AADI Quant Ranking